#United States #New York #Securities Fraud #Pomerantz LLP #Valneva SE

Introduction

In recent developments, Pomerantz LLP has initiated an investigation into Valneva SE, a biotechnology company based in France and traded on NASDAQ under the symbol VALN. This investigation arises from allegations suggesting that Valneva and its executives may have engaged in activities constituting securities fraud or other illegal business practices.

Background of the Investigation

On March 31, 2025, Pomerantz LLP made a public announcement inviting investors of Valneva SE who may have suffered losses to come forward. This investigation was sparked by a significant notice posted by the U.S. Centers for Disease Control and Prevention (CDC) on February 25, 2025, which reported that the agency was investigating several cardiac or neurological events that were noted in patients aged 65 and older after vaccination with IXCHIQ, Valneva's chikungunya virus vaccine.

Following the CDC's announcement, Valneva's American Depositary Receipt (ADR) suffered a notable decline, falling by $1.06 per ADR, which translates to a 13.57% decrease, closing at $6.75 per ADR just three days later. This decline raised concerns among investors, prompting them to question the company’s transparency and the reliability of their vaccine information.

The Role of Pomerantz LLP

Pomerantz LLP is a well-regarded firm specializing in corporate, securities, and antitrust class-action litigation. With a history spanning more than 85 years, it has built a reputation as a champion for victims of securities fraud and corporate misconduct. Founded by the late Abraham L. Pomerantz, who is often referred to as the dean of the class action bar, the firm has a longstanding tradition of fighting for investor rights and has secured significant financial recoveries for investors in the past.

This particular investigation aims to determine whether Valneva and its leadership engaged in manipulative behaviors that misrepresented the company’s operations or the safety of its products. Such legal scrutiny is essential for holding corporations accountable and ensuring investors have access to truthful information when making investment decisions.

How Investors Can Respond

Investors who believe they may have suffered financial losses due to their engagement with Valneva SE are encouraged to reach out to Pomerantz LLP. Those who wish to participate in the investigation or seek legal counsel can contact attorney Danielle Peyton, either through email or by phone, as provided in the Pomerantz announcement.

The firm’s proactive invitation to investors underscores the importance of collective legal action in addressing grievances related to securities fraud and corporate malfeasance.

Conclusion

The ongoing investigation by Pomerantz LLP into Valneva SE illustrates the necessity for transparency in the biotech industry, especially in the ever-critical realm of vaccine development and deployment. With the serious implications of the CDC's findings, both investors and the public must remain vigilant and informed about the activities of companies they are associated with, particularly when safety and health are at stake. The outcomes of these legal inquiries could prove significant not only for Valneva’s investors but also for public confidence in the safety of their medical products.